NCCN Bladder Cancer Guidelines: Analyzing Racial and Ethnic Clinical Trial Reporting
A study presented at the 2026 ASCO meeting reveals that less than half of the clinical trials cited in NCCN Bladder Cancer Guidelines report racial or ethnic participant data. Researchers emphasize that while reporting has improved over time, the lack of demographic transparency in standard care references remains a concern.
Why it matters
Improving demographic reporting in clinical trials is essential for ensuring that medical guidelines are equitable and effective for diverse patient populations.
Breast Cancer GI Cancer Colorectal Cancer GI Cancer Awareness and Advocacy GU Cancer Bladder Cancer Gyn-Onc Uterine Cancer Awareness Month Gynecologic Cancer Awareness Month Hem/Onc Blood Cancer Awareness Month GVHD Leukemia Lymphoma Myeloproliferative Neoplasms Multiple Myeloma Myelodysplastic Syndrome Myelofibrosis Sickle Cell Immunotherapy More Professional Development Patient Voice Lung Cancer Skin Cancer Other Tumor Types News Treatment Menu Home > Bladder Cancer > NCCN Bladder Cancer Guidelines: Analyzing Racial and Ethnic Clinical Trial Reporting
The report summarizes medical research findings objectively without taking a political stance.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in